Eli Lilly is trading 4.79% up at ARS 41,960, with today’s move possibly reflecting continued reaction to its October 29 third-quarter results and raised outlook. - Revenue rose 39% to $24.4 billion, led by Mounjaro and Zepbound. - Lilly raised its 2026 revenue outlook to $91 billion–$92 billion, from $85 billion–$87 billion. - Available reporting chiefly linked the earnings and guidance news to the prior session’s surge.